New research in Scientific Reports reveals that COVID-19 survivors, especially those who had severe or critical illness, face long-term lung complications and a reduced quality of life. The study recommends 6-monthly pulmonary function tests for these survivors to monitor for chronic lung damage.
Turnstone charts $75M IPO for TIL cell therapies in drumroll of biotech IPOs this month
Turnstone Biologics plans to list on the Nasdaq in a $75 million raise shortly after a trio of biotechs — Apogee Therapeutics, Sagimet Biosciences and
July 18, 2023